ECOG is as independent predictor of the response to chemotherapy, overall survival and progression-free survival in carcinoma of unknown primary site
The aim of the present study was to determine whether age, gender, functional status, histology, tumor location, number of metastases, and levels of the tumor markers, lactate dehydrogenase (LDH) and albumin, are poor prognostic factors for the response to chemotherapy in patients with carcinoma of...
Gespeichert in:
| Veröffentlicht in: | Molecular and clinical oncology 2017-05, Vol.6 (5), p.643-650 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 650 |
|---|---|
| container_issue | 5 |
| container_start_page | 643 |
| container_title | Molecular and clinical oncology |
| container_volume | 6 |
| creator | Grajales-Álvarez, Rocío Martin-Aguilar, Ana Silva, Juan A De La Garza-Salazar, Jaime G Ruiz-García, Erika López-Camarillo, César Marchat, Laurence A La Vega, Horacio Astudillo-De |
| description | The aim of the present study was to determine whether age, gender, functional status, histology, tumor location, number of metastases, and levels of the tumor markers, lactate dehydrogenase (LDH) and albumin, are poor prognostic factors for the response to chemotherapy in patients with carcinoma of unknown primary site. A total of 149 patients diagnosed with carcinoma of unknown primary site that was histologically confirmed, and treated with chemotherapy in the Oncology Hospital, National Medical Center, 'Century XXI' IMSS, Mexico City, Mexico during the period between January 2002 to December 2009, were carefully selected for the present study. The analysis of 149 patients diagnosed with carcinoma of unknown primary site revealed that the liver was the organ with the highest frequency of metastases (33.5%). The objective response rates to chemotherapy were ~30.2%. Notably, ECOG was an important predictor of response to chemotherapy (P=0.008). The median progression-free survival was 7.1 months. Upon multivariate analysis, the Eastern Cooperative Oncology Group (ECOG) Scale of Performance Status was observed as an independent predictor of progression (P |
| doi_str_mv | 10.3892/mco.2017.1209 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5431331</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A496086111</galeid><sourcerecordid>A496086111</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-2f06c6ae002ffd1761c0d339835043357d610b518b38dbcddb5ca7965fe6e81b3</originalsourceid><addsrcrecordid>eNptUl1vFCEUnRiNbdY--mpIfPHBWfkYGHgxaTa1mjTpiz4TBu7sUmdghZk1_SH-X5l03VojELi595wLh5yqek3wmklFP4w2rikm7ZpQrJ5V5xQ3qlaNUM9PMcdn1UXOd7gM1WLK1cvqjEpOuCLivPp1tbm9Rj4jk5EPDvZQtjChfQLn7RQTij2adoAS5H0MGdAUkd3BGEsymf39exQPJRgGlOd08AczIBNc4cdtoWQfQ90ngMeqD8iaZH2Io1maz-F7iD9DYfjRpHuU_QSvqhe9GTJcHM9V9e3T1dfN5_rm9vrL5vKmtk0rp5r2WFhhAGPa9460gljsGFOScdwwxlsnCO44kR2TrrPOddyaVgnegwBJOraqPj703c_dCM4W5UWKPj5FR-P100rwO72NB80bRlhZq-rdsUGKP2bIkx59tjAMJkCcsyYKY0IVl6xA3_4DvYtzCkVeQalGUUEkeURtzQDahz6We-3SVF82SmApCFlQ6_-gynQwehsD9L7knxDqB4JNMecE_UkjwXqxki5W0ouV9GKlgn_z98ec0H-Mw34DwArGgQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1994926181</pqid></control><display><type>article</type><title>ECOG is as independent predictor of the response to chemotherapy, overall survival and progression-free survival in carcinoma of unknown primary site</title><source>Spandidos Publications Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Grajales-Álvarez, Rocío ; Martin-Aguilar, Ana ; Silva, Juan A ; De La Garza-Salazar, Jaime G ; Ruiz-García, Erika ; López-Camarillo, César ; Marchat, Laurence A ; La Vega, Horacio Astudillo-De</creator><creatorcontrib>Grajales-Álvarez, Rocío ; Martin-Aguilar, Ana ; Silva, Juan A ; De La Garza-Salazar, Jaime G ; Ruiz-García, Erika ; López-Camarillo, César ; Marchat, Laurence A ; La Vega, Horacio Astudillo-De</creatorcontrib><description>The aim of the present study was to determine whether age, gender, functional status, histology, tumor location, number of metastases, and levels of the tumor markers, lactate dehydrogenase (LDH) and albumin, are poor prognostic factors for the response to chemotherapy in patients with carcinoma of unknown primary site. A total of 149 patients diagnosed with carcinoma of unknown primary site that was histologically confirmed, and treated with chemotherapy in the Oncology Hospital, National Medical Center, 'Century XXI' IMSS, Mexico City, Mexico during the period between January 2002 to December 2009, were carefully selected for the present study. The analysis of 149 patients diagnosed with carcinoma of unknown primary site revealed that the liver was the organ with the highest frequency of metastases (33.5%). The objective response rates to chemotherapy were ~30.2%. Notably, ECOG was an important predictor of response to chemotherapy (P=0.008). The median progression-free survival was 7.1 months. Upon multivariate analysis, the Eastern Cooperative Oncology Group (ECOG) Scale of Performance Status was observed as an independent predictor of progression (P<0.0001). The median overall survival was 14.2 months. The ECOG was also an independent predictor of mortality (P<0.0001). In conclusion, the data from the present study have demonstrated that ECOG is an independent predictor of a poor response to chemotherapy, lower overall survival and progression-free survival in carcinoma of unknown primary site.</description><identifier>ISSN: 2049-9450</identifier><identifier>EISSN: 2049-9469</identifier><identifier>DOI: 10.3892/mco.2017.1209</identifier><identifier>PMID: 28515916</identifier><language>eng</language><publisher>England: Spandidos Publications</publisher><subject>Age ; Biomarkers ; Cancer ; Carcinoma ; Care and treatment ; Chemotherapy ; Confidence intervals ; Dehydrogenases ; Development and progression ; Gender ; Histology ; Medical prognosis ; Metastasis ; Multivariate analysis ; Nervous system ; Oncology ; Patient outcomes ; Patients ; Prognosis ; Statistical analysis ; Variables</subject><ispartof>Molecular and clinical oncology, 2017-05, Vol.6 (5), p.643-650</ispartof><rights>COPYRIGHT 2017 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2017</rights><rights>Copyright: © Grajales-Álvarez et al. 2017</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-2f06c6ae002ffd1761c0d339835043357d610b518b38dbcddb5ca7965fe6e81b3</citedby><cites>FETCH-LOGICAL-c478t-2f06c6ae002ffd1761c0d339835043357d610b518b38dbcddb5ca7965fe6e81b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431331/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431331/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28515916$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grajales-Álvarez, Rocío</creatorcontrib><creatorcontrib>Martin-Aguilar, Ana</creatorcontrib><creatorcontrib>Silva, Juan A</creatorcontrib><creatorcontrib>De La Garza-Salazar, Jaime G</creatorcontrib><creatorcontrib>Ruiz-García, Erika</creatorcontrib><creatorcontrib>López-Camarillo, César</creatorcontrib><creatorcontrib>Marchat, Laurence A</creatorcontrib><creatorcontrib>La Vega, Horacio Astudillo-De</creatorcontrib><title>ECOG is as independent predictor of the response to chemotherapy, overall survival and progression-free survival in carcinoma of unknown primary site</title><title>Molecular and clinical oncology</title><addtitle>Mol Clin Oncol</addtitle><description>The aim of the present study was to determine whether age, gender, functional status, histology, tumor location, number of metastases, and levels of the tumor markers, lactate dehydrogenase (LDH) and albumin, are poor prognostic factors for the response to chemotherapy in patients with carcinoma of unknown primary site. A total of 149 patients diagnosed with carcinoma of unknown primary site that was histologically confirmed, and treated with chemotherapy in the Oncology Hospital, National Medical Center, 'Century XXI' IMSS, Mexico City, Mexico during the period between January 2002 to December 2009, were carefully selected for the present study. The analysis of 149 patients diagnosed with carcinoma of unknown primary site revealed that the liver was the organ with the highest frequency of metastases (33.5%). The objective response rates to chemotherapy were ~30.2%. Notably, ECOG was an important predictor of response to chemotherapy (P=0.008). The median progression-free survival was 7.1 months. Upon multivariate analysis, the Eastern Cooperative Oncology Group (ECOG) Scale of Performance Status was observed as an independent predictor of progression (P<0.0001). The median overall survival was 14.2 months. The ECOG was also an independent predictor of mortality (P<0.0001). In conclusion, the data from the present study have demonstrated that ECOG is an independent predictor of a poor response to chemotherapy, lower overall survival and progression-free survival in carcinoma of unknown primary site.</description><subject>Age</subject><subject>Biomarkers</subject><subject>Cancer</subject><subject>Carcinoma</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Confidence intervals</subject><subject>Dehydrogenases</subject><subject>Development and progression</subject><subject>Gender</subject><subject>Histology</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Multivariate analysis</subject><subject>Nervous system</subject><subject>Oncology</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Statistical analysis</subject><subject>Variables</subject><issn>2049-9450</issn><issn>2049-9469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptUl1vFCEUnRiNbdY--mpIfPHBWfkYGHgxaTa1mjTpiz4TBu7sUmdghZk1_SH-X5l03VojELi595wLh5yqek3wmklFP4w2rikm7ZpQrJ5V5xQ3qlaNUM9PMcdn1UXOd7gM1WLK1cvqjEpOuCLivPp1tbm9Rj4jk5EPDvZQtjChfQLn7RQTij2adoAS5H0MGdAUkd3BGEsymf39exQPJRgGlOd08AczIBNc4cdtoWQfQ90ngMeqD8iaZH2Io1maz-F7iD9DYfjRpHuU_QSvqhe9GTJcHM9V9e3T1dfN5_rm9vrL5vKmtk0rp5r2WFhhAGPa9460gljsGFOScdwwxlsnCO44kR2TrrPOddyaVgnegwBJOraqPj703c_dCM4W5UWKPj5FR-P100rwO72NB80bRlhZq-rdsUGKP2bIkx59tjAMJkCcsyYKY0IVl6xA3_4DvYtzCkVeQalGUUEkeURtzQDahz6We-3SVF82SmApCFlQ6_-gynQwehsD9L7knxDqB4JNMecE_UkjwXqxki5W0ouV9GKlgn_z98ec0H-Mw34DwArGgQ</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Grajales-Álvarez, Rocío</creator><creator>Martin-Aguilar, Ana</creator><creator>Silva, Juan A</creator><creator>De La Garza-Salazar, Jaime G</creator><creator>Ruiz-García, Erika</creator><creator>López-Camarillo, César</creator><creator>Marchat, Laurence A</creator><creator>La Vega, Horacio Astudillo-De</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170501</creationdate><title>ECOG is as independent predictor of the response to chemotherapy, overall survival and progression-free survival in carcinoma of unknown primary site</title><author>Grajales-Álvarez, Rocío ; Martin-Aguilar, Ana ; Silva, Juan A ; De La Garza-Salazar, Jaime G ; Ruiz-García, Erika ; López-Camarillo, César ; Marchat, Laurence A ; La Vega, Horacio Astudillo-De</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-2f06c6ae002ffd1761c0d339835043357d610b518b38dbcddb5ca7965fe6e81b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Age</topic><topic>Biomarkers</topic><topic>Cancer</topic><topic>Carcinoma</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Confidence intervals</topic><topic>Dehydrogenases</topic><topic>Development and progression</topic><topic>Gender</topic><topic>Histology</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Multivariate analysis</topic><topic>Nervous system</topic><topic>Oncology</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Statistical analysis</topic><topic>Variables</topic><toplevel>online_resources</toplevel><creatorcontrib>Grajales-Álvarez, Rocío</creatorcontrib><creatorcontrib>Martin-Aguilar, Ana</creatorcontrib><creatorcontrib>Silva, Juan A</creatorcontrib><creatorcontrib>De La Garza-Salazar, Jaime G</creatorcontrib><creatorcontrib>Ruiz-García, Erika</creatorcontrib><creatorcontrib>López-Camarillo, César</creatorcontrib><creatorcontrib>Marchat, Laurence A</creatorcontrib><creatorcontrib>La Vega, Horacio Astudillo-De</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grajales-Álvarez, Rocío</au><au>Martin-Aguilar, Ana</au><au>Silva, Juan A</au><au>De La Garza-Salazar, Jaime G</au><au>Ruiz-García, Erika</au><au>López-Camarillo, César</au><au>Marchat, Laurence A</au><au>La Vega, Horacio Astudillo-De</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ECOG is as independent predictor of the response to chemotherapy, overall survival and progression-free survival in carcinoma of unknown primary site</atitle><jtitle>Molecular and clinical oncology</jtitle><addtitle>Mol Clin Oncol</addtitle><date>2017-05-01</date><risdate>2017</risdate><volume>6</volume><issue>5</issue><spage>643</spage><epage>650</epage><pages>643-650</pages><issn>2049-9450</issn><eissn>2049-9469</eissn><abstract>The aim of the present study was to determine whether age, gender, functional status, histology, tumor location, number of metastases, and levels of the tumor markers, lactate dehydrogenase (LDH) and albumin, are poor prognostic factors for the response to chemotherapy in patients with carcinoma of unknown primary site. A total of 149 patients diagnosed with carcinoma of unknown primary site that was histologically confirmed, and treated with chemotherapy in the Oncology Hospital, National Medical Center, 'Century XXI' IMSS, Mexico City, Mexico during the period between January 2002 to December 2009, were carefully selected for the present study. The analysis of 149 patients diagnosed with carcinoma of unknown primary site revealed that the liver was the organ with the highest frequency of metastases (33.5%). The objective response rates to chemotherapy were ~30.2%. Notably, ECOG was an important predictor of response to chemotherapy (P=0.008). The median progression-free survival was 7.1 months. Upon multivariate analysis, the Eastern Cooperative Oncology Group (ECOG) Scale of Performance Status was observed as an independent predictor of progression (P<0.0001). The median overall survival was 14.2 months. The ECOG was also an independent predictor of mortality (P<0.0001). In conclusion, the data from the present study have demonstrated that ECOG is an independent predictor of a poor response to chemotherapy, lower overall survival and progression-free survival in carcinoma of unknown primary site.</abstract><cop>England</cop><pub>Spandidos Publications</pub><pmid>28515916</pmid><doi>10.3892/mco.2017.1209</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2049-9450 |
| ispartof | Molecular and clinical oncology, 2017-05, Vol.6 (5), p.643-650 |
| issn | 2049-9450 2049-9469 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5431331 |
| source | Spandidos Publications Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Age Biomarkers Cancer Carcinoma Care and treatment Chemotherapy Confidence intervals Dehydrogenases Development and progression Gender Histology Medical prognosis Metastasis Multivariate analysis Nervous system Oncology Patient outcomes Patients Prognosis Statistical analysis Variables |
| title | ECOG is as independent predictor of the response to chemotherapy, overall survival and progression-free survival in carcinoma of unknown primary site |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T17%3A32%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ECOG%20is%20as%20independent%20predictor%20of%20the%20response%20to%20chemotherapy,%20overall%20survival%20and%20progression-free%20survival%20in%20carcinoma%20of%20unknown%20primary%20site&rft.jtitle=Molecular%20and%20clinical%20oncology&rft.au=Grajales-%C3%81lvarez,%20Roc%C3%ADo&rft.date=2017-05-01&rft.volume=6&rft.issue=5&rft.spage=643&rft.epage=650&rft.pages=643-650&rft.issn=2049-9450&rft.eissn=2049-9469&rft_id=info:doi/10.3892/mco.2017.1209&rft_dat=%3Cgale_pubme%3EA496086111%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1994926181&rft_id=info:pmid/28515916&rft_galeid=A496086111&rfr_iscdi=true |